Pembrolizumab Improves PFS in Hodgkin Lymphoma Compared With Brentuximab Vedotin
John Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.